Last reviewed · How we verify
NPB-01-ME
NPB-01-ME is a methyl ester prodrug formulation designed to improve the bioavailability and pharmacokinetic properties of its active parent compound.
At a glance
| Generic name | NPB-01-ME |
|---|---|
| Also known as | methylprednisolone sodium succinate |
| Sponsor | Nihon Pharmaceutical Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
NPB-01-ME is a modified formulation of an existing pharmaceutical agent, where the methyl ester modification (-ME) typically serves to enhance oral absorption, stability, or tissue penetration. The prodrug is metabolized in vivo to release the active parent compound at the site of action, potentially improving therapeutic efficacy and reducing systemic exposure-related adverse effects.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |